Vaxart Gets $12.5M For Oral Vaccines

San Francisco-based Vaxart, a developer of oral vaccines, said today that it has raised $12.5M in a Series B funding round. The round was led by Care Capital. As part of the funding, Richard Markham and Jan Leschly of Care Capital have joined the firm's board of directors. Vaxart said it will use the funding to advance its lead product, an oral vaccine for Avian influenza, through Phase I clinical trials. More information »